[go: up one dir, main page]

WO1996030523A3 - Antigen presentation system based on retrovirus-like particles - Google Patents

Antigen presentation system based on retrovirus-like particles Download PDF

Info

Publication number
WO1996030523A3
WO1996030523A3 PCT/EP1996/001433 EP9601433W WO9630523A3 WO 1996030523 A3 WO1996030523 A3 WO 1996030523A3 EP 9601433 W EP9601433 W EP 9601433W WO 9630523 A3 WO9630523 A3 WO 9630523A3
Authority
WO
WIPO (PCT)
Prior art keywords
particles
presentation system
antigen presentation
retrovirus
system based
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1996/001433
Other languages
French (fr)
Other versions
WO1996030523A2 (en
Inventor
Hans Wolf
Ralf Wagner
Ludwig Deml
Klaus Osterrieder
Frank Notka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to EP96911989A priority Critical patent/EP0817854A2/en
Publication of WO1996030523A2 publication Critical patent/WO1996030523A2/en
Publication of WO1996030523A3 publication Critical patent/WO1996030523A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention relates to the provision of an antigen presentation system on the basis of a DNA sequence encoding a protein capable of self assembly into particles without a lipid membrane, preferably a retroviral group-specific antigen (gag) that can be used, e.g., for the preventive and therapeutic immunization of mammals against infectious diseases or neoplasias.
PCT/EP1996/001433 1995-03-31 1996-04-01 Antigen presentation system based on retrovirus-like particles Ceased WO1996030523A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP96911989A EP0817854A2 (en) 1995-03-31 1996-04-01 Antigen presentation system based on retrovirus-like particles

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP95104849 1995-03-31
EP95104850 1995-03-31
EP95104849.5 1995-03-31
EP95104848.7 1995-03-31
EP95104848 1995-03-31
EP95104850.3 1995-03-31

Publications (2)

Publication Number Publication Date
WO1996030523A2 WO1996030523A2 (en) 1996-10-03
WO1996030523A3 true WO1996030523A3 (en) 1997-04-17

Family

ID=27236505

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1996/001433 Ceased WO1996030523A2 (en) 1995-03-31 1996-04-01 Antigen presentation system based on retrovirus-like particles

Country Status (3)

Country Link
EP (1) EP0817854A2 (en)
CN (1) CN1185811A (en)
WO (1) WO1996030523A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7348177B2 (en) 1998-12-31 2008-03-25 Novartis Vaccines And Diagnostics, Inc. Expression of HIV polypeptides and production of virus-like particles

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE412434T1 (en) 1998-11-30 2008-11-15 Cytos Biotechnology Ag MOLECULAR ARRANGEMENT OF ALLERGENS, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
JP2003523721A (en) 1998-12-31 2003-08-12 カイロン コーポレイション Polynucleotides encoding antigenic HIVC-type polypeptides, polypeptides, and uses thereof
US20040014033A1 (en) 1999-06-30 2004-01-22 Evotec Biosystems Ag, A Corporation Of Germany Virus like particles, their preparation and their use preferably in pharmaceutical screening and functional genomics
EP1187928B1 (en) * 1999-06-30 2007-05-23 Evotec AG Virus like particles, preparation and use in screening and functional genomics
US7476517B2 (en) 1999-06-30 2009-01-13 Evotec Ag Virus like particles, their preparation and their use preferably in pharmaceutical screening and functional genomics
DE19957838C2 (en) 1999-11-25 2002-11-21 Pette Heinrich Inst Gene therapy of HIV-infected people through expression of membrane-anchored gp41 peptides
US20020106798A1 (en) * 2000-03-02 2002-08-08 Robinson Harriet L. DNA expression vectors and methods of use
AU2001252458A1 (en) 2000-05-05 2001-11-20 Martin Bachmann Molecular antigen arrays and vaccines
EP1219705B1 (en) * 2000-12-29 2007-11-28 Evotec AG Virus like particles, their preparation and their use preferably in pharmaceutical screening and functional genomics
US7094409B2 (en) 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
US7264810B2 (en) 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
US7128911B2 (en) 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
AU2002320314A1 (en) 2001-07-05 2003-01-21 Chiron, Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
EP2280074A3 (en) 2001-07-05 2011-06-22 Novartis Vaccines and Diagnostics, Inc. Polynucleotides encoding antigenic HIV type B and/or type C polypeptides, polypeptides and uses thereof
WO2003012085A1 (en) * 2001-07-30 2003-02-13 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Antigen presenting cells, method for their preparation and their use for cancer vaccines
WO2003024481A2 (en) 2001-09-14 2003-03-27 Cytos Biotechnology Ag Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
US7115266B2 (en) 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
MXPA04002644A (en) 2001-10-05 2004-07-08 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof.
EP1532167B1 (en) 2002-07-17 2012-01-25 Cytos Biotechnology AG Molecular antigen arrays using a virus like particle derived from the ap205 coat protein
CN100518823C (en) 2002-07-18 2009-07-29 赛托斯生物技术公司 Hapten-carrier conjugates and uses thereof
KR20100125480A (en) 2002-07-19 2010-11-30 사이토스 바이오테크놀로지 아게 Vaccine composition comprising amyloid beta 1-6 antigen array
US7537767B2 (en) 2003-03-26 2009-05-26 Cytis Biotechnology Ag Melan-A- carrier conjugates
CN100560719C (en) 2003-03-26 2009-11-18 赛托斯生物技术公司 Melan-A peptide analog-virus-like particle conjugates
EP1814583A2 (en) 2004-11-01 2007-08-08 Novartis Vaccines and Diagnostics, Inc. Combination approaches for generating immune responses
JP5302671B2 (en) 2005-03-18 2013-10-02 サイトス バイオテクノロジー アーゲー Cat allergen conjugates and uses thereof
EP1736538A1 (en) 2005-06-21 2006-12-27 Cytos Biotechnology AG Process for the preparative purification of virus-like-particles (VLPs)
CN103230590A (en) 2005-09-28 2013-08-07 赛托斯生物技术公司 Interleukin-1 conjugates and uses thereof
WO2007068747A1 (en) 2005-12-14 2007-06-21 Cytos Biotechnology Ag Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
KR101552227B1 (en) 2006-06-12 2015-09-10 사이토스 바이오테크놀로지 아게 Methods of packaging oligonucleotides into virus-like particles of RNA bacteriophage
US9296790B2 (en) 2008-10-03 2016-03-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for protein delivery
BRPI0922561A2 (en) 2008-12-09 2020-08-11 Pfizer Vaccines Llc ige ch3 peptide vaccine.
AU2010277254B2 (en) 2009-07-30 2015-05-07 Pfizer Vaccines Llc Antigenic tau peptides and uses thereof
KR101512053B1 (en) 2009-09-03 2015-04-28 화이자 백신스 엘엘씨 Pcsk9 vaccine
EP2942061A3 (en) 2010-06-07 2016-01-13 Pfizer Vaccines LLC Ige ch3 peptide vaccine
EP2680883B1 (en) 2011-03-02 2018-09-05 Pfizer Inc Pcsk9 vaccine
US20140004146A1 (en) * 2011-03-17 2014-01-02 Institut Pasteur Of Shanghai, Chinese Academy Of Sciences Method for producing virus-like particle by using drosophila cell and applications thereof
WO2013148302A1 (en) 2012-03-26 2013-10-03 THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, OFFICE OF TECHNOLOGY TRANSFER, NATIONAL INSTITUTES OF HEALTH Delivery of packaged rna to mammalian cells
EP3659620B1 (en) 2013-12-16 2021-08-11 The United States of America, As Represented by the Secretary, Dept. of Health & Human Services Office of Technology Transfer Cancer immunotherapy by delivering class ii mhc antigens and a costimulatory signal protein using a vlp-replicon
WO2015101666A1 (en) 2014-01-03 2015-07-09 Fundación Biofísica Bizkaia VLPs, METHODS FOR THEIR OBTENTION AND APPLICATIONS THEREOF
WO2015123291A1 (en) 2014-02-11 2015-08-20 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Pcsk9 vaccine and methods of using the same
CN104450631A (en) * 2014-11-11 2015-03-25 中国人民解放军第四军医大学 Enterovirus EV71 type VP1 gene virus-like particle as well as preparation method and application thereof
CN105177031B (en) * 2015-06-12 2018-04-24 北京艺妙神州医疗科技有限公司 T cell of Chimeric antigen receptor modification and application thereof
WO2017179025A1 (en) 2016-04-15 2017-10-19 Alk-Abelló A/S Epitope polypeptides of ragweed pollen allergens
WO2019173438A1 (en) 2018-03-06 2019-09-12 Stc. Unm Compositions and methods for reducing serum triglycerides
CN119286871A (en) 2018-04-19 2025-01-10 查美特制药公司 Synthetic RIG-I-like receptor agonists
MX2022004825A (en) 2019-10-23 2022-10-10 Regeneron Pharma SYNTHETIC AGONISTS OF THE RIG I-LIKE RECEPTOR.
EP4164681A1 (en) 2020-06-12 2023-04-19 GlaxoSmithKline Biologicals S.A. Bacterial immunization using nanoparticle vaccine
WO2023111826A1 (en) 2021-12-14 2023-06-22 Glaxosmithkline Biologicals Sa Bacterial immunization using qbeta hairpin nanoparticle constructs
CN118634321B (en) * 2024-06-28 2025-02-28 重庆医科大学附属第一医院 A preparation method for covalently coupling adjuvant and antigen of P24 virus-like particles

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991005864A1 (en) * 1989-10-13 1991-05-02 Connaught Laboratories Limited Production of genetically-engineered vaccines for aids and other retroviral diseases
WO1991007425A1 (en) * 1989-11-20 1991-05-30 Oncogen Limited Partnership Non-replicating recombinant-made retroviral particles used as antiviral agents and immunogens
WO1991019803A1 (en) * 1990-06-19 1991-12-26 Applied Biotechnology, Incorporated Self assembled, defective, nonself-propagating viral particles
WO1992003537A1 (en) * 1990-08-15 1992-03-05 Therion Biologics Corporation Self-assembling replication defective hybrid virus particles
EP0508809A1 (en) * 1991-04-10 1992-10-14 British Bio-Technology Limited Proteinaceous lipid-containing particles
CA2098029A1 (en) * 1993-06-09 1994-12-10 Benjamin Rovinski Retrovirus-Like Particles Containing Modified Envelope Glycoproteins
WO1996005292A1 (en) * 1994-08-15 1996-02-22 Connaught Laboratories Limited Antigenically-marked non-infectious retrovirus-like particles

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991005864A1 (en) * 1989-10-13 1991-05-02 Connaught Laboratories Limited Production of genetically-engineered vaccines for aids and other retroviral diseases
WO1991007425A1 (en) * 1989-11-20 1991-05-30 Oncogen Limited Partnership Non-replicating recombinant-made retroviral particles used as antiviral agents and immunogens
WO1991019803A1 (en) * 1990-06-19 1991-12-26 Applied Biotechnology, Incorporated Self assembled, defective, nonself-propagating viral particles
WO1992003537A1 (en) * 1990-08-15 1992-03-05 Therion Biologics Corporation Self-assembling replication defective hybrid virus particles
EP0508809A1 (en) * 1991-04-10 1992-10-14 British Bio-Technology Limited Proteinaceous lipid-containing particles
CA2098029A1 (en) * 1993-06-09 1994-12-10 Benjamin Rovinski Retrovirus-Like Particles Containing Modified Envelope Glycoproteins
WO1996005292A1 (en) * 1994-08-15 1996-02-22 Connaught Laboratories Limited Antigenically-marked non-infectious retrovirus-like particles

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
M. MOTZ ET AL.: "Truncated versions of two major Epstein-Barr viral glycoproteins are secreted by recombinant chinese hamster ovary cells", GENE, vol. 58, 1987, pages 149 - 154, XP002027077 *
N. OSTERRIEDER ET AL.: "Expression of equine herpesvirus type 1 glycoprotein in E. coli and insect cells", J. GEN. VIROL., vol. 75, 1994, pages 2041 - 2046, XP002027076 *
N. OSTERRIEDER ET AL.: "Protection against EHV1 challenge infection in the murine model after vaccination with various formulations of recombinant glycoprotein gp14 (gB)", VIROLOGY, vol. 208, 1995, pages 500 - 510, XP002027079 *
O. HAFFAR ET AL.: "Human immunodeficiency virus-like, non-replicating gag-env particles assemble in a recombinant vaccinia virus expression system", J. VIROL., vol. 64, no. 6, 1990, pages 2653 - 2659, XP002027078 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7348177B2 (en) 1998-12-31 2008-03-25 Novartis Vaccines And Diagnostics, Inc. Expression of HIV polypeptides and production of virus-like particles

Also Published As

Publication number Publication date
WO1996030523A2 (en) 1996-10-03
CN1185811A (en) 1998-06-24
EP0817854A2 (en) 1998-01-14

Similar Documents

Publication Publication Date Title
WO1996030523A3 (en) Antigen presentation system based on retrovirus-like particles
PT1012295E (en) ALFAVIRUS RNA REPLICATION SYSTEMS
AU642403B2 (en) Method for the use and synthesis of peptides
EP2042512A3 (en) Polynucleic acids and proteins from a porcine reproductive and respiratory syndrome virus and uses thereof
NO973250L (en) Preparations for delivery of antigens
WO1996033730A3 (en) Chemokine binding protein and methods of use therefor
EP1203817A3 (en) Compounds and methods for immunotherapy and diagnosis of tuberculosis
WO1995029193A3 (en) Melanoma antigens
AU4005295A (en) Compositions for the delivery of antigens
EP2311952A3 (en) Antibodies to MRT-1 protein or fragments thereof
ATE207931T1 (en) DEVICE FOR PURIFYING AND MODIFYING PEPTIDES
EP1849869A3 (en) Nucleotide sequences of HIV-1 group (or sub-group) 0 retroviral antigens
WO1999036568A3 (en) Method for identifying t-cell stimulating protein fragments
AU4826493A (en) Anti-feline immunodeficiency virus (fiv) vaccines
AU3772289A (en) Endotoxin binding protein and uses thereof
AU6612294A (en) Process for producing hydrophobic polypeptides, proteins or peptides
DK610888A (en) CARDIODILATE INGREDIENT, METHOD OF PREPARING THEREOF AND ITS USE
WO1996007739A3 (en) Interleukin-1 type 3 receptors
DE69128039D1 (en) ALLERGENS FROM RYE SPOOLS
AU3390995A (en) Novel implant and novel vector for the treatment of acquired diseases
AU3384495A (en) Or-1 on orphan receptor belonging to the nuclear receptor family
AU3283199A (en) Novel peptide diagnostic reagent and kit for detection of rickettsiosis
WO1999021994A3 (en) Human vesicle membrane protein-like proteins
WO1996013723A3 (en) Marker for pathologies comprising an auto-immune reaction and/or for inflammatory diseases
WO2002052270A3 (en) Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 96194306.8

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): BR CA CN JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1996911989

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 1998 930672

Country of ref document: US

Date of ref document: 19980102

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1996911989

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1996911989

Country of ref document: EP